ANTX - CIK 0001880438
The table below shows AN2 Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $6.74M | $7.00M | $3.20M | $7.69M | $8.29M | $12.15M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $3.81M |
| $3.04M |
| $4.02M |
| $3.85M |
| $3.48M |
| $3.73M |
| Operating income | -$10.55M | -$10.04M | -$7.22M | -$11.54M | -$14.01M | -$15.88M |
| Income tax | - | - | - | - | - | - |
| Net income | -$10.03M | -$9.35M | -$6.46M | -$10.65M | -$12.75M | -$14.44M |
| EPS (diluted) | -$0.29 | -$0.31 | -$0.21 | -$0.35 | -$0.43 | -$0.48 |